Premium
FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2
Author(s) -
Coutre S. E.,
Barr P. M.,
Owen C.,
Robak T.,
Tedeschi A.,
Bairey O.,
Burger J. A.,
Hillmen P.,
Devereux S.,
Grosicki S.,
McCarthy H.,
Li J.,
Simpson D.,
Offner F.,
Moreno C.,
Dai S.,
Szoke A.,
Dean J. P.,
Kipps T. J.,
Ghia P.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.48_2880
Subject(s) - ibrutinib , chlorambucil , medicine , hazard ratio , ighv@ , chronic lymphocytic leukemia , neutropenia , oncology , confidence interval , gastroenterology , leukemia , chemotherapy , cyclophosphamide